| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 4393- | AgNPs, | Nanotoxic Effects of Silver Nanoparticles on Normal HEK-293 Cells in Comparison to Cancerous HeLa Cell Line |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | HEK293 |
| 4433- | AgNPs, | Advancements in metal and metal oxide nanoparticles for targeted cancer therapy and imaging: Mechanisms, applications, and safety concerns |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Nor, | L02 |
| 4551- | AgNPs, | Fenb, | Ångstrom-Scale Silver Particles as a Promising Agent for Low-Toxicity Broad-Spectrum Potent Anticancer Therapy |
| - | in-vivo, | Lung, | NA |
| 1563- | Api, | MET, | Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells |
| - | in-vitro, | Nor, | HDFa | - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | NA, | NA |
| 5195- | DCA, | Rad, | Dichloroacetate Radiosensitizes Hypoxic Breast Cancer Cells |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | BC, | EMT6 |
| 4473- | SeNPs, | Anti-cancerous effect and biological evaluation of green synthesized Selenium nanoparticles on MCF-7 breast cancer and HUVEC cell lines |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | HUVECs |
| 4453- | SeNPs, | Selenium Nanoparticles: Green Synthesis and Biomedical Application |
| - | Review, | NA, | NA |
| 1736- | SFN, | Antitumor and antimetastatic effects of dietary sulforaphane in a triple-negative breast cancer models |
| - | in-vitro, | BC, | NA | - | in-vivo, | BC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1110 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid